The approval of liso-cel is another big step forward because now we have three products. Liso-cel has shown excellent efficacy in several different lymphoma entities, transformed follicular lymphomas, but also in the classical indications, diffuse large B-cell lymphoma after second-line.
I think with this new product, which is different from the other two in a way that the ratio between T4 and T8 is balanced, will give us new opportunities...
The approval of liso-cel is another big step forward because now we have three products. Liso-cel has shown excellent efficacy in several different lymphoma entities, transformed follicular lymphomas, but also in the classical indications, diffuse large B-cell lymphoma after second-line.
I think with this new product, which is different from the other two in a way that the ratio between T4 and T8 is balanced, will give us new opportunities. We’ve had the chance to use the product in clinical studies. I think we will also see approval in Europe pretty soon. Of course, that will help us to broaden the possibilities for our patients. One particular aspect, maybe, with the liso-cel, of course, is that in the studies, there were also some patients with CNS involvement included, which will also broaden our armamentarium in terms of applying this product to this kind of patients, where other products have, at least, not been studied in detail.